Importantly, these high-risk tumors were associated with RB1 inactivation, indicating a higher probability of resistance to CDK4/6 inhibitors25, a therapeutic class improving survival in ER/PR-positive/HER2-negative advanced breast cancers and currently under investigation in the adjuvant setting26–32. Here, CDK4 is linked to breast cancer.